Maher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina-Molina, M., . . . Cottin, V. (2020). Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: A double-blind, randomised, placebo-controlled, phase 2 trial. The lancet. Respiratory medicine, 8(2), . https://doi.org/10.1016/S2213-2600(19)30341-8
Chicago-Zitierstil (17. Ausg.)Maher, Toby M., et al. "Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease: A Double-blind, Randomised, Placebo-controlled, Phase 2 Trial." The Lancet. Respiratory Medicine 8, no. 2 (2020). https://doi.org/10.1016/S2213-2600(19)30341-8.
MLA-Zitierstil (9. Ausg.)Maher, Toby M., et al. "Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease: A Double-blind, Randomised, Placebo-controlled, Phase 2 Trial." The Lancet. Respiratory Medicine, vol. 8, no. 2, 2020, https://doi.org/10.1016/S2213-2600(19)30341-8.